10X Historical Income Statement
| TXG Stock | USD 26.92 2.36 8.06% |
Historical analysis of 10X Genomics income statement accounts such as Depreciation And Amortization of 45.8 M, Interest Expense of 31.4 K, Selling General Administrative of 212.1 M or Total Revenue of 375.2 M can show how well 10X Genomics performed in making a profits. Evaluating 10X Genomics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of 10X Genomics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining 10X Genomics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 10X Genomics is a good buy for the upcoming year.
10X |
About 10X Income Statement Analysis
10X Genomics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to 10X Genomics shareholders. The income statement also shows 10X investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
10X Genomics Income Statement Chart
10X Genomics Income Statement is one of the three primary financial statements used for reporting 10X's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of 10X Genomics revenue and expense. 10X Genomics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, 10X Genomics' Depreciation And Amortization is most likely to increase significantly in the upcoming years. The 10X Genomics' current Cost Of Revenue is estimated to increase to about 219.9 M, while Interest Expense is projected to decrease to roughly 31.4 K. Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Total Revenue
Total revenue comprises all receipts 10X Genomics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of 10X Genomics minus its cost of goods sold. It is profit before 10X Genomics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Operating Income
Operating Income is the amount of profit realized from 10X Genomics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of 10X Genomics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from 10X Genomics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into 10X Genomics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.At this time, 10X Genomics' Depreciation And Amortization is most likely to increase significantly in the upcoming years. The 10X Genomics' current Cost Of Revenue is estimated to increase to about 219.9 M, while Interest Expense is projected to decrease to roughly 31.4 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 416.4M | 396.0M | 409.3M | 286.8M | Total Revenue | 490.5M | 516.4M | 618.7M | 375.2M |
10X Genomics income statement Correlations
Click cells to compare fundamentals
10X Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
10X Genomics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 218K | 8.3M | 4.5M | 4.0M | 6.3M | 3.7M | |
| Net Interest Income | (274K) | (150K) | (660K) | 6.2M | 16.9M | 17.7M | |
| Interest Income | 2.8M | 1.5M | 206K | 6.6M | 16.9M | 17.8M | |
| Depreciation And Amortization | 2.6M | 2.9M | (596K) | 6.4M | 43.6M | 45.8M | |
| Interest Expense | 3.1M | 1.7M | 866K | 476K | 33K | 31.4K | |
| Selling General Administrative | 129.3M | 200.4M | 252.9M | 294.6M | 337.5M | 212.1M | |
| Total Revenue | 245.9M | 298.8M | 490.5M | 516.4M | 618.7M | 375.2M | |
| Gross Profit | 184.9M | 240.4M | 416.4M | 396.0M | 409.3M | 286.8M | |
| Other Operating Expenses | 275.0M | 384.2M | 543.4M | 684.4M | 820.6M | 465.3M | |
| Operating Income | (29.1M) | (85.3M) | (52.9M) | (167.9M) | (201.9M) | (191.8M) | |
| Net Income From Continuing Ops | (31.3M) | (542.7M) | (58.2M) | (166M) | (255.1M) | (267.9M) | |
| Ebit | (29.1M) | (85.3M) | (52.9M) | (167.9M) | (201.9M) | (191.8M) | |
| Research Development | 83.1M | 123.4M | 211.8M | 265.7M | 270.3M | 162.5M | |
| Ebitda | (26.5M) | (82.5M) | (53.5M) | (161.5M) | (158.2M) | (150.3M) | |
| Cost Of Revenue | 61.0M | 58.5M | 74.1M | 120.4M | 209.4M | 219.9M | |
| Total Operating Expenses | 213.9M | 325.7M | 469.3M | 564.0M | 611.2M | 376.9M | |
| Reconciled Depreciation | 7.1M | 19.0M | 28.3M | 33.0M | 43.6M | 21.9M | |
| Income Before Tax | (31.0M) | (534.5M) | (53.7M) | (162.0M) | (248.8M) | (261.2M) | |
| Total Other Income Expense Net | (2.0M) | (449.2M) | (802K) | 6.0M | (46.9M) | (49.2M) | |
| Net Income Applicable To Common Shares | (31.3M) | (542.7M) | (58.2M) | (166M) | (149.4M) | (156.9M) | |
| Net Income | (31.3M) | (542.7M) | (58.2M) | (166M) | (255.1M) | (267.9M) | |
| Income Tax Expense | 218K | 8.3M | 4.5M | 4.0M | 6.3M | 3.7M |
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is 10X Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 5.281 | Quarterly Revenue Growth 0.178 | Return On Assets (0.12) | Return On Equity (0.33) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.